B-ring-aryl substituted luotonin A analogues with a new binding mode to the topoisomerase 1-DNA complex show enhanced cytotoxic activity

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  González Ruiz, Víctor ^a   Pascua, Irene ^a,b   Fernández Marcelo, Tamara ^a,b   Ribelles, Pascual ^a   Bianchini, Giulia ^a   Sridharan, Vellaisamy ^a,c   Iniesta, Pilar ^a,b   Teresa Ramos, M ^a   Olives, Ana I ^a   Antonia Martin M ^a   Carlos Menendez J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c SASTRA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM NITRATE; ARGININE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CERIUM; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; GUANINE; LUOTONIN A DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; AMINO ACID; ANTINEOPLASTIC AGENT; DNA; LIGAND; LUOTONIN A; NITRIC ACID DERIVATIVE; PROTEIN BINDING; PYRROLE DERIVATIVE; QUINONE DERIVATIVE; TOP1 PROTEIN, HUMAN;

ARTICLE; BINDING KINETICS; CATALYSIS; CHEMICAL REACTION; COMPLEX FORMATION; CYTOTOXICITY ASSAY; DNA PROTEIN COMPLEX; DRUG ACTIVITY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DEVELOPMENT; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; CHEMISTRY; CONFORMATION; CRYSTALLIZATION; HELA CELL LINE; HUMAN; MEDICINAL CHEMISTRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; SYNTHESIS;

AMINO ACIDS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CERIUM; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DNA; DNA TOPOISOMERASES, TYPE I; HELA CELLS; HUMANS; HYDROGEN BONDING; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR CONFORMATION; NITRATES; PROTEIN BINDING; PYRROLES; QUINONES; TOPOISOMERASE I INHIBITORS;

EID: 84901368879     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095998     Document Type: Article

References (38)

1. Ferlay J, Soerjomataram EM, Dikshit R, Eser S, Mathers C, et al. (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available: http://globocan.iarc.fr, accessed on 22/01/2014.
2. Levin B, Boyle P (Eds.) (2008) World cancer report. Lyon: International Agency for Research on Cancer, WHO Press.
3. Avendaño C, Menéndez JC (2008) Medicinal chemistry of anticancer drugs. Amsterdam: Elsevier.
4. Chen SH, Chan NL, Hsieh TS (2013) New mechanistic and functional insights into DNA topoisomerases. Ann Rev Biochem 82: 139-170.
5. Pommier Y (2011) DNA topoisomerases and cancer. New York: Springer.
6. Pommier Y (2013) Drugging topoisomerases: Lessons and challenges. ACS Chem Biol 8: 82-95.
7. Kacprzak KM (2013) Chemistry and biology of camptothecin and its derivatives, in Ramawat KG, Mérillon JM (Eds.) Natural Products (643-682) Heidelberg, Berlin: Springer.
8. Castelli S, Coletta A, D'Anness I, Fiorani P, Tesauro C, et al. (2012) Interaction between natural compounds and human topoisomerase 1. Biol Chem 393: 1327-1340.
9. Venditto VJ, Simanek EE (2010) Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharmaceutics 7: 307-349.
10. Pommier Y (2009) DNA topoisomerase 1 inhibitors: Chemistry, biology, and interfacial inhibition. Chem Rev 109: 2894-2902.
11. Marszałł MP, Buciński A, Kruszewski S, Ziomkowska B (2011) A new approach to determine camptothecin and its analogues affinity to human serum albumin. J Pharm Sci 100: 1142-1146.
12. Pizzolato JF, Saltz LB (2003) The camptothecins. Lancet 361: 2235-2242.
13. Cagir A, Jones SH, Gao R, Eisenhauer BMA, Hecht SM (2003) Luotonin A. A naturally occurring human DNA topoisomerase 1 poison. J Am Chem Soc 125: 13628-13629.
14. Dallavalle S, Merlini L, Beretta G, Tinelli S, Zunino F (2004) Synthesis and cytotoxic activity of substituted luotonin A derivatives. Bioorg Med Chem Lett 14: 5757-5761.
15. Liang JL, Cha HC, Jahng Y (2011) Recent advances in the studies on luotonins. Molecules 16: 4861-4883.
16. Tseng MC, Chu YW, Tsai HP, Lin CM, Hwang J, et al. (2011) One-pot synthesis of luotonin A and its analogues. Org Lett 13: 920-923.
17. Boisse T, Gavara L, Gautret P, Baldeyrou B, Lansiaux A, et al. (2011) Toward new camptothecins. Part 7: Synthesis of thioluotonine and its 5-methoxycarbonyl derivative. Tetrahedron Lett 52: 1592-1596.
18. Golubev AS, Bogomolov VO, Shidlovskii AF, Dezhenkova LG, Peregudov AS, et al. (2011) Synthesis of fluoromethyl-containing analogs of antitumor alkaloid luotonin A. Russ Chem Bull, Int Edition 59: 209-218.
19. Sridharan V, Ribelles P, Ramos MT, Menéndez JC (2009) Cerium(IV) ammonium nitrate is an excellent, general catalyst for the Friedländer and Friedländer-Borsche quinoline syntheses: Very efficient access to the antitumor alkaloid luotonin A. J Org Chem 74: 5715-5718.
20. Atechian S, Nock N, Norcross RD, Ratni H, Thomas AW, et al. (2007) New vistas in quinoline synthesis. Tetrahedron 63: 2811-2823.
21. Ma ZZ, Hano Y, Nomura T, Chen YJ (1997) Two new pyrroloquinazolinoquinoline alkaloids from Peganum nigellastrum. Heterocycles 46: 541-546.
22. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature Protocols 1: 1112-1116.
23. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, et al. (2002) The mechanism of topoisomerase 1 poisoning by a camptothecin analog. Proc Natl Acad Sci USA 99: 15387-15392.
24. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera - A visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612.
25. Dunbrack Jr RL (2002) Rotamer libraries in the 21st century. Curr Opin Struct Biol 12: 431-440.
26. Wang J, Wang W, Kollman PA, Case DA (2006) Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Modelling 25: 247-260.
27. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al. (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J Comput Chem 16: 2785-2791.
28. Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput Chem 31: 455-461.
29. Molina P, Tárraga A, González-Tejero A (2000) A convenient divergent approach to the alkaloids isaindigotone and luotonin A. Synthesis 1523-1525.
30. Sridharan V, Menéndez JC (2010) Cerium(IV) ammonium nitrate as a catalyst in organic synthesis. Chem Rev 110: 3805-3849.
31. Rahman AFMM, Kim DH, Liang JL, Lee ES, Na Y, et al. (2008) Synthesis and biological properties of luotonin A derivatives. Bull Kor Chem Soc 29: 1988-1992.
32. Marco JL, Pérez-Mayoral E, Samadi A, Carreiras MC, Soriano E (2009) Recent advances in the Friedländer reaction. Chem Rev 109: 2652-2671.
33. Politzer P, Murray JS, Clark T (2013) Halogen bonding and other s-hole interactions: A perspective. Phys Chem Chem Phys 15: 11178-11189.
34. Howard EI, Sanishvili R, Cachau RE, Mitschler A, Chevrier B, et al. (2004) Ultrahigh resolution drug design I: Details of interactions in human aldose reductase-inhibitor complex at 0.66 Å. Prot Struct Funct Bioin, 55: 792-804.
35. González-Ruiz V, Mussardo P, Corda E, Girotti S, Olives AI, et al. (2010) Liquid chromatographic analysis of the anticancer alkaloid luotonin A and some new derivatives in human serum samples. J Sep Sci 33: 2086-2093.
36. Verma RP, Hansch C (2009) Camptothecins: A SAR/QSAR study. Chem Rev 109: 213-235.
37. Available: www.chemicalize.org.Accessed on 22/01/2014.
38. Wadkins RM, Bearss D, Manikumar G, Wani MC, Wall ME, et al. (2004) Topoisomerase 1-DNA complex stability induced by camptothecins and its role in drug activity. Curr Med Chem-Anti- Cancer Agents 4: 327-334.